Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Zanidatamab for HER2+ Localized Colorectal Cancer
NCT07405476Phase 2Recruiting
- Sponsor
- Emory University
- Start
- Apr 2026
- Primary completion
- Dec 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of zanidatamab in colorectal cancer (CRC), colon cancer, rectal cancer, sponsored by Emory University. Started Apr 2026; status: recruiting.
02
Drugs
zanidatamab
03
Conditions
colorectal cancer (CRC)colon cancerrectal cancer
Beyond the preview
Go deeper on NCT07405476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07405476.